OBJECTIVE: In people with screen-detected type 2 diabetes in primary care, (1) to assess adherence to guidelines, recommending consultation with the GP every three months and treatment initiation with an ACE inhibitor or an angiotensin-II receptor antagonist when systolic BP was > 120 mmHg and/or diastolic BP was > 80 mmHg, and (2) to identify predictors for adherence. DESIGN: Prospective follow-up of a fixed cohort of patients. SETTING: Fifty-four Danish general practices. SUBJECTS AND MAIN OUTCOME MEASURES: A total of 361 people with screen-detected type 2 diabetes were followed up for 410 days to assess planned consultations with their GP and recording of BP. Some 226 people, with BP recorded above guideline threshold(s) and where treatment was not already initiated, were followed for up to 410 days to monitor prescription redemption. RESULTS: At 3, 6, 9 and 12 months 80%, 77%, 74%, and 73% of the cohort attended a consultation. A total of 89% of the cohort attended two of the four planned consultations. The probability of redeemed prescriptions for an ACE inhibitor or an angiotensin-II receptor antagonist according to the guideline during the first year following diagnosis was 51%. High initial BP was associated with prescription redemption. No other analysed individual or organisational characteristics were found to be associated with treatment initiation. CONCLUSION: The consultation attendance was reasonably high, and treatment initiation with an ACE inhibitor or an angiotensin-II receptor antagonist according to the guideline was found in half of the cases. High initial BP increased the probability of treatment initiation.
OBJECTIVE: In people with screen-detected type 2 diabetes in primary care, (1) to assess adherence to guidelines, recommending consultation with the GP every three months and treatment initiation with an ACE inhibitor or an angiotensin-II receptor antagonist when systolic BP was > 120 mmHg and/or diastolic BP was > 80 mmHg, and (2) to identify predictors for adherence. DESIGN: Prospective follow-up of a fixed cohort of patients. SETTING: Fifty-four Danish general practices. SUBJECTS AND MAIN OUTCOME MEASURES: A total of 361 people with screen-detected type 2 diabetes were followed up for 410 days to assess planned consultations with their GP and recording of BP. Some 226 people, with BP recorded above guideline threshold(s) and where treatment was not already initiated, were followed for up to 410 days to monitor prescription redemption. RESULTS: At 3, 6, 9 and 12 months 80%, 77%, 74%, and 73% of the cohort attended a consultation. A total of 89% of the cohort attended two of the four planned consultations. The probability of redeemed prescriptions for an ACE inhibitor or an angiotensin-II receptor antagonist according to the guideline during the first year following diagnosis was 51%. High initial BP was associated with prescription redemption. No other analysed individual or organisational characteristics were found to be associated with treatment initiation. CONCLUSION: The consultation attendance was reasonably high, and treatment initiation with an ACE inhibitor or an angiotensin-II receptor antagonist according to the guideline was found in half of the cases. High initial BP increased the probability of treatment initiation.
Authors: Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen Journal: N Engl J Med Date: 2003-01-30 Impact factor: 91.245
Authors: Annemieke M W Spijkerman; Marcel C Adriaanse; Jacqueline M Dekker; Giel Nijpels; Coen D A Stehouwer; Lex M Bouter; Robert J Heine Journal: Diabetes Care Date: 2002-10 Impact factor: 19.112
Authors: Patrik Midlöv; Rickard Ekesbo; Lennart Johansson; Sofia Gerward; Kristin Persson; Christina Nerbrand; Bo Hedblad Journal: Scand J Prim Health Care Date: 2008 Impact factor: 2.581
Authors: Anni B S Nielsen; Dorte Gannik; Volkert Siersma; Niels de Fine Olivarius Journal: Scand J Prim Health Care Date: 2011-06-27 Impact factor: 2.581
Authors: Morten Charles; Rebecca K Simmons; Kate M Williams; Gojka Roglic; Stephen J Sharp; Ann-Louise Kinmonth; Nicholas J Wareham; Simon J Griffin Journal: Br J Gen Pract Date: 2012-06 Impact factor: 5.386
Authors: Poul Erik Heldgaard; Jan Erik Henriksen; Johannes J Sidelmann; Niels de Fine Olivarius; Volkert D Siersma; Jørgen B Gram Journal: Scand J Prim Health Care Date: 2011-03-28 Impact factor: 2.581
Authors: Rachel Gold; Arwen Bunce; Stuart Cowburn; James V Davis; Celine Hollombe; Christine A Nelson; Jon Puro; John Muench; Christian Hill; Victoria Jaworski; MaryBeth Mercer; Colleen Howard; Nancy Perrin; Jennifer DeVoe Journal: BMC Health Serv Res Date: 2017-04-05 Impact factor: 2.655